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ABSTRACT Accurate determination of the genetic diversity present in the HIV qua-
sispecies is critical for the development of a preventative vaccine: in particular, little
is known about viral genetic diversity for the second type of HIV, HIV-2. A better un-
derstanding of HIV-2 biology is relevant to the HIV vaccine ﬁeld because a substan-
tial proportion of infected people experience long-term viral control, and prior HIV-2
infection has been associated with slower HIV-1 disease progression in coinfected
subjects. The majority of traditional and next-generation sequencing methods have
relied on target ampliﬁcation prior to sequencing, introducing biases that may ob-
scure the true signals of diversity in the viral population. Additionally, target enrich-
ment through PCR requires a priori sequence knowledge, which is lacking for HIV-2.
Therefore, a target enrichment free method of library preparation would be valuable
for the ﬁeld. We applied an RNA shotgun sequencing (RNA-Seq) method without
PCR ampliﬁcation to cultured viral stocks and patient plasma samples from HIV-2-
infected individuals. Libraries generated from total plasma RNA were analyzed with a
two-step pipeline: (i) de novo genome assembly, followed by (ii) read remapping. By
this approach, whole-genome sequences were generated with a 28 to 67 mean
depth of coverage. Assembled reads showed a low level of GC bias, and comparison
of the genome diversities at the intrahost level showed low diversity in the acces-
sory gene vpx in all patients. Our study demonstrates that RNA-Seq is a feasible full-
genome de novo sequencing method for blood plasma samples collected from HIV-
2-infected individuals.
IMPORTANCE An accurate picture of viral genetic diversity is critical for the devel-
opment of a globally effective HIV vaccine. However, sequencing strategies are often
complicated by target enrichment prior to sequencing, introducing biases that can
distort variant frequencies, which are not easily corrected for in downstream analy-
ses. Additionally, detailed a priori sequence knowledge is needed to inform robust
primer design when employing PCR ampliﬁcation, a factor that is often lacking
when working with tropical diseases localized in developing countries. Previous
work has demonstrated that direct RNA shotgun sequencing (RNA-Seq) can be used
to circumvent these issues for hepatitis C virus (HCV) and norovirus. We applied
RNA-Seq to total RNA extracted from HIV-2 blood plasma samples, demonstrating
the applicability of this technique to HIV-2 and allowing us to generate a dynamic
picture of genetic diversity over the whole genome of HIV-2 in the context of low-
bias sequencing.
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Human immunodeﬁciency virus types 1 and 2 (HIV-1 and HIV-2), the two causativeagents of AIDS, are human pathogens of high importance (1). Following the
introduction of HIV-1 and HIV-2 into human populations through zoonotic transmission
of simian immunodeﬁciency viruses (SIVs) infecting several species of apes and non-
human primates, HIV-1 and HIV-2 are estimated to have infected more than 75 million
people worldwide, resulting in over 40 million deaths (2).
While HIV-1 and HIV-2 share some common features, a major difference between
the two viruses is the typical viral load (VL) associated with chronic infection. In patients
infected with HIV-2, viral load is strongly correlated with disease progression, and a
large proportion (37% in the Caió cohort) maintained undetectable viral loads and
high CD4 counts in the absence of treatment during follow-up (sometimes for more
than two decades) (3). In addition, based on previous data from this cohort, subjects
with VLs of 10,000 were regarded as having a high likelihood of subsequent pro-
gression (4). Indeed, patients with a viral load of more than 10,000 copies/ml have been
suggested to be HIV-2 progressors with a reduced survival probability that is similar to
that seen in HIV-1-infected individuals in the absence of treatment (5). Furthermore,
lack of HIV-2 control is associated with lower viral loads than for HIV-1 in patients
matched by disease stage (4, 6–8).
HIV-1 disease progression has also been correlated with viral coreceptor use or
molecular properties like glycosylation patterns, charge, and length of the envelope
gene (9–12). Although cytopathic CXCR4-using virions have been isolated from HIV-2-
infected individuals in late-stage disease (13, 14), less is known about correlations
between molecular properties and disease stage in HIV-2 infection, particularly outside
the envelope gene (15, 16). One of the main barriers to a globally protective HIV vaccine
is the ability of HIV to evolve rapidly, introducing mutations that abrogate the binding
of neutralizing antibodies, rendering vaccine responses ineffective (17). Therefore, a
major focus of HIV research has been to understand the factors affecting viral evolution
and to identify viral epitopes of high conservation as potential vaccine targets (18).
Due to the relatively low copy number of the small-sized HIV single-stranded RNA
(ssRNA) genome (10,000 bases), target enrichment is normally required prior to
sequencing in order to generate sufﬁcient DNA for downstream sequencing applica-
tions (19). The most common method of target enrichment is PCR ampliﬁcation (20).
This method has two major drawbacks. The ﬁrst is the requirement for detailed a priori
sequence knowledge to inform robust primer design that ensures that the majority of
variants in the viral quasispecies are captured (21). Different ampliﬁcation strategies
have shown sensitivities down to 3,000 copies/ml, demonstrating the difﬁculty of
generating robust and high-depth sequence data from patients without detectable
plasma viremia (22, 23). However, the sequence database for HIV-2 is signiﬁcantly
smaller than for HIV-1, and a robust and sensitive pan-HIV-2 primer set has yet to be
deﬁned and thoroughly evaluated. Mutations in primer binding sites can also reduce
binding efﬁciency and therefore alter the proportion of speciﬁc variants in the ﬁnal pool
of amplicons or, in extreme cases, abrogate primer binding completely, resulting in the
loss of that variant in the ﬁnal analysis (24). The second drawback is that PCR is
stochastically biased by amplicons from previous cycles acting as templates in the
subsequent ampliﬁcation cycles with the potential to further distort the picture of the
viral diversity (25).
Several methods have been proposed to circumvent these problems and reduce the
biases introduced into sequencing data through target enrichment. For example,
primer identiﬁcation (ID) allows identiﬁcation of reads derived from the same viral
template through incorporation of a unique 8-mer tag during the reverse transcription
of viral RNA (26). Downstream reads can be pooled according to template, and multiple
reads from the same template can be used for error correction. A study using primer
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ID observed biased diversity estimates between 2- and 100-fold compared to a library
generated without any PCR bias correction, highlighting the importance of considering
this factor when sequencing a highly diverse population, such as HIV (26). However,
primer ID still relies on sufﬁcient a priori sequence knowledge to allow robust primer
design, and the incorporation of the barcode into the 3= end of the cDNA molecule
means that it is not applicable to library preparation techniques involving random
fragmentation of the target, such as those employed when using Illumina platforms.
Shotgun RNA sequencing (RNA-Seq) has been demonstrated as a powerful tool for
the study of RNA viruses (27). Library preparation is performed using random-hexamer
priming of the total RNA in a sample, negating the need for sequence-speciﬁc target
enrichment (28). This is particularly desirable for HIV-2, for which the sequence data
available are signiﬁcantly limited compared with those for HIV-1. Few studies have
applied RNA-Seq to human RNA viruses. For example, Ninomiya et al. applied RNA-Seq
to plasma samples taken from two chronically hepatitis C virus (HCV)-infected patients
and demonstrated nearly full-length genome sequences with a mean depth of cover-
age between 50 to 70 for the two patients (29). In another study, Batty et al. further
expanded this method, presenting a high-throughput method for norovirus sequenc-
ing allowing 77 fecal samples to be sequenced, with a mean depth of coverage of 100
and a success rate of more than 99% (30). The authors compared this with a PCR
ampliﬁcation strategy and found that the success rate for whole-genome ampliﬁcation
using PCR was 29%. This represents a signiﬁcant decrease in the performance com-
pared to that of RNA-Seq. RNA-Seq has also been used for the discovery of two novel
SIVs, demonstrating the power of this method of sequencing without prior sequence
information in viral discovery (31).
In the present study, we applied RNA-Seq library preparation methods to both
patient plasma samples taken from a rural West African community cohort and cultured
lab-adapted HIV-2 reference strains. We show that RNA-Seq followed by de novo
assembly is a feasible and powerful approach when applied to HIV-2 samples with viral
loads of at least 5,280 copies/ml. In addition, we demonstrate that RNA-Seq represents
a novel, low-bias method of HIV-2 sequencing. Finally, we computed estimates of
nucleotide diversity for each gene of HIV-2 on both the intra- and interhost levels.
These analyses indicated consistently low estimates of diversity in the accessory gene
vpx within hosts, highlighting the importance of this HIV-2-speciﬁc gene in successful
HIV-2 infection.
RESULTS
Patient and sample characteristics. Samples from a panel of six members of the
Caió HIV-2 community cohort (TD003, TD006, TD013, TD024, TD031, and TD062), whose
plasma viral loads represented the broad spectrum seen in natural HIV-2 infection, as
well as cultures of two lab-adapted HIV-2 strains (HIV-2 ROD and HIV-2 CBL20) were
subjected to standard RNA-Seq library preparation (Table 1).
Assessment of RNA-Seq using HIV-2 ROD. First, we assessed the performance of
RNA-Seq using the well-characterized reference strain HIV-2 ROD. Following initial
TABLE 1 Clinical data related to the analyzed samples and controlsa
Sample Sampling year Sexb Country CD4 (cells/l) Viral load (cp/ml)c
Clinical status at
sample date
TD003 2010 F Guinea-Bissau 560 82,005 Asymptomatic
TD006 2010 F Guinea-Bissau 1,176 50 Asymptomatic
TD013 2010 M Guinea-Bissau 509 1,632 Asymptomatic
TD024 2010 F Guinea-Bissau 191 10,560 AIDS
TD031 2010 F Guinea-Bissau 407 107,183 Asymptomatic
TD062 2010 M Guinea-Bissau 497 139,519 Asymptomatic
CBL20 1988 M The Gambia 18 NA AIDS
ROD 1985 M Cape Verde 100 NA AIDS
aPatients samples included TD003 to TD062. Controls included CBL20 and ROD.
bF, female; M, male.
cAs determined by an in-house RT-PCR assay (66). cp, copies.
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quality control and removal of low-quality reads and adaptor contamination, reads
were assessed for the presence of biased random-hexamer priming. The random-
hexamer analysis indicated that a random-hexamer bias affected the ﬁrst 13 bp of the
read. The remaining high-quality reads were assembled to the HIV-2 ROD reference
genome sequence (accession number BD413542). The mean depth of coverage over
the whole genome was around 2,000 for all alignment tools, with GSNAP having the
highest mean depth (Table 2). All four alignment tools produced a slightly positive GC
bias, and more GC-rich regions tended to have higher coverage. The slopes were very
similar (0.79 to 0.91), implying that the assembly algorithm used does not affect the GC
bias. In order to assess how divergent the HIV-2 ROD that was propagated for the
present study was from the published reference sequence, polymorphisms that were
ﬁxed at a frequency of 95% in the sample population were annotated as single
nucleotide polymorphisms (SNPs) using VarScan (Fig. 1). The BWA-SW build was used
for this analysis, as it agreed with the majority consensus at each site of conﬂict. All
genes except vif had SNPs (in total 70 SNPs), and the majority of SNPs were seen in gag,
pol, and nef. However, when corrected for gene length, nef showed the greatest
contribution to divergence from the reference genome.
De novo genome assembly and factors influencing RNA-Seq success rate. After
showing that our RNA-Seq approach could be used for whole-genome sequencing of
a high-copy number and lab-adapted HIV-2 strain, we assessed the feasibility of using
RNA-Seq to generate whole-genome sequences directly from primary patient blood
plasma samples (Table 1). Clinical blood plasma samples often contain signiﬁcant
amounts of human RNA, making it challenging to perform de novo assembly of minority
species (such as HIV-2). VICUNA is designed to target populations with high mutation
rates and map minority variants into a single consensus sequence and is therefore
particularly suitable for HIV-2, considering the few publicly available HIV-2 whole-
genome sequences. In addition, since HIV-2 blood plasma samples usually have sig-
niﬁcantly lower viral copy numbers than propagated virus isolates, we included a
lab-adapted HIV-2 strain derived from a Gambian subject (CBL20), for which the
whole-genome sequence is unknown, as a high-viremia control (Table 1).
In total, whole-genome assembly was successful for three of the six patient samples
(TD024, TD031, and TD062) and the control (CBL20). Successful patient samples showed
complete capture of the protein-coding region of HIV-2 and merged contigs ranged
from 9,397 to 9776 bp in length. A merged contig spanning the complete coding
region was also assembled for CBL20, demonstrating the applicability of RNA-Seq to
both in vitro and ex vivo samples. Although we are unable to provide a formal cutoff
value, these results suggest that a viral load of at least 5,000 copies/ml is needed for
successful sequencing, with an expectation of at least 0.001% HIV-derived RNA (Table
3). When these limits are considered, the success rate was 75%.
In order to assess how well de novo assembly using VICUNA had captured the HIV-2
genome, consensus sequences were aligned to the commonly used HIV-2 group A
reference sequence UC2 (accession number U38293) and annotated according to
homology (Table S1). In patient sample TD031, the ﬁrst 177 bp of the gag leader
sequence was missing, whereas the long terminal repeat (LTR) region lacked coverage
for patient samples TD024 and TD062 and the reference strain CBL20.
TABLE 2 Summary of read mapping to sample-speciﬁc reference sequences
Sample ID
Bowtie2 BWA-SW GSNAP NovoAlign
Mean
depth
Reads
aligning
Mean
depth
Reads
aligning
Mean
depth
Reads
aligning
Mean
depth
Reads
aligning
TD024 28.53 3,709 31.90 3,988 27.69 3,426 27.79 3,463
TD031 62.33 7,658 67.23 8,044 60.33 7,172 60.50 7,267
TD062 50.01 6,617 59.61 7,468 45.92 5,658 46.64 5,751
CBL20 5,502 539,906 4,734 412,557 6,451 618,464 5,156 432,538
ROD 1,924 165,506 1,794 152,105 2,146 176,885 1,862 155,696
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Phylogenetic analysis of de novo genome sequences. A BLAST analysis of the
newly generated sequences indicated highest similarity with HIV-2 group A sequences.
Bayesian phylogenetic analysis with the 20 publicly available HIV-2 group A near
full-genome sequences conﬁrmed this (Fig. 2; Table S1). This analysis also showed that
the newly generated sequences were clearly distinguishable from existing reference
sequences. As expected, the HIV-2 ROD sequence generated in the present study and
the published reference sequence were closely related and clustered together, with a
posterior probability of 1.
Read remapping to the patient-specific consensus whole-genome sequences.
In contrast to resequencing projects, in which a high depth of coverage is required for
error correction, deep sequencing of pathogen populations uses high depth of cover-
age to gain a picture of the diversity in the population as a whole (27). Following de
novo assembly of a patient-speciﬁc consensus genome sequence, we assessed the
FIG 1 Divergence in vitro of the lab-adapted HIV-2 isolate HIV-2 ROD. Assembled reads were visualized in Integrative Genomics Viewer (54) and mismatched
sites were colored (A). Sites of conservation with the published reference sequence are shown in gray. Single nucleotide polymorphisms (SNPs) were deﬁned
as ﬁxed at a frequency of 95%, and the total number of SNPs in each gene was calculated (B). In order to allow for varying gene lengths, the frequency of
SNPs in each gene was also calculated (C).
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performance of four commonly used alignment tools when remapping reads to the
patient-speciﬁc consensus (Table 2). Read remapping was performed using the total
reads without prior HIV-2 enrichment or digital subtraction of human sequences to
allow an assessment of how these tools perform in the context of a high level of
contamination. This is likely to be a factor of all pathogen sequencing strategies
employing RNA-Seq. Mean depth and range of coverage were compared for each
aligner (Fig. 3). These results show consistent performance of the four aligners, with
mean depths of coverage ranging from 28 to 67 for the three patient samples. This
range is in line with previous RNA-Seq studies, showing that RNA-Seq is a feasible tool
for generating HIV-2 whole-genome sequences. Additionally, the high similarity indi-
cates that read mapping is robust and repeatable irrespective of which alignment
TABLE 3 Samples included in the present study and de novo assembly statistics
Sample ID
No. of viral
copiesa
Total RNA
(ng)b
Predicted HIV
RNA (%)c
No. of reads aligning
to viral reference
Genome covered
by all contigs (%)
No. of genes
intact
Merged contig
length (bp)
TD003 41,002 8.70 0.0023 0 0 0 0
TD006 50 7.65 0.0000033 0 0 0 0
TD013 816 34.00 0.000012 0 0 0 0
TD024 5,280 2.30 0.0011 4,998 93 9 9,531
TD031 53,591 3.10 0.0087 9,065 90 9 9,397
TD062 69,759 2.85 0.012 13,304 87 9 9,776
CBL20 10,000,000 9.65 20 930,072 87 9 9,885
aAbsolute viral input estimated from viral load.
bTotal RNA input used for library preparation.
cEstimated using a viral genome length of 10 kb and absolute viral input.
FIG 2 Bayesian phylogeny of HIV-2 genome sequences generated in the present study. Eighteen whole-genome
HIV-2 group A sequences were included as a reference set (Table S1). Reference sequences are colored according
to country of origin, and sequences generated in the present study are shown in red. Bayesian posterior
probabilities are included on the corresponding nodes, and the scale bar represents the number of nucleotide
substitutions per site.
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algorithm is employed following de novo assembly of patient-speciﬁc consensus se-
quences. Error rates were consistent over cycles, and there was no evidence of a drop
in accuracy over the length of the read (Fig. 4).
Assessment of the random-hexamer bias. A commonly recognized bias that is
speciﬁc to RNA-Seq protocols is the random-hexamer bias (32, 33). Hypothetical
differential binding afﬁnities between different random hexamers result in biased
nucleotide composition at the 3= ends of the reads, normally spanning 7 to 13 bp. In
line with previous studies and our initial assessment of RNA-Seq using HIV-2 ROD, the
random-hexamer analysis indicated that a random hexamer bias affected the ﬁrst 13 bp
of the read (Fig. S1). The pattern of the bias was similar in all three patient samples and
FIG 3 Depth of coverage with the four different aligners. Depth of coverage for each locus was plotted
for TD024 (A), TD031 (B), and TD062 (C). Open rectangles represent the locations of HIV-2 genes, and the
position of the longest merged contig is also shown for each sample. Coverage plots are shown for each
of the four aligners, Bowtie2, GSNP, BWA-SW, and NovoAlign. Coverage was plotted as raw depth,
showing the number of reads mapping to each locus.
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the control (CBL20), suggesting that there may be preferential binding to the same
motifs in all samples. This biased read composition can be attributed to random-
hexamer bias rather than low-quality sequencing at the end of the reads, as the median
Q-score was constant over the length of the read. The effect of the bias did not extend
past the ﬁrst 13 bp of each read, and the nucleotide composition stabilized after this
point. A correction was not applied to account for the biased nucleotide composition
of the ﬁrst 13 bp, as removal of these positions does not remove the effects of this bias
seen in downstream analyses.
Quantification of the GC bias and depth of coverage as a function of genomic
context. Depth of coverage in samples sequenced using Illumina short-read chemistry
can be affected by the local GC content of the genome (34). We assessed the effect of
local GC content on depth of coverage using a custom script which took a sliding
window of 50 bp, with a step size of 20 bp, and calculated percent GC and mean depth
of coverage in each window. The extent of the GC bias was quantiﬁed using the slope
of the linear regression line, and the bias was assessed for each aligner individually
(Table 4). To further compare the different aligners, the mean depth of coverage was
normalized in each window using the genome-wide mean depth of coverage (Fig. 5).
All assemblies showed a slight, positive GC bias, suggesting that GC-rich regions had a
depth of coverage that was higher than the mean. For patient samples TD024 and
TD031, the magnitudes of the slope were similar for all four aligners, suggesting a
constant effect when different assembly algorithms were employed. In contrast, sample
TD062 showed more ﬂuctuation between aligners. However, the magnitude of the bias
was lowest for this patient, suggesting that the overall effect of the GC bias would be
reduced, in spite of the ﬂuctuations. Hence, a positive GC bias in HIV-2 samples
sequenced using RNA-Seq may confer variability in depth of coverage over the ge-
nome. However, the magnitude of the bias was in line with previous studies and did not
show a loss of coverage of any genomic regions due to GC bias (34).
In order to assess whether genomic context could affect depth of coverage, the
HIV-2 genome was partitioned according to gene and mean depth of coverage was
compared for each gene individually. The effect of genomic context on depth of
FIG 4 Error rate per sequencing cycle. Error rates were estimated for each sample using the GATK package using the
number of mismatches seen during each cycle and the recalibrated quality score of each position. This gave an estimation
of error rate per cycle for each of the 100 sequencing cycles for the ﬁrst read set of each pair. Error rates per cycle were
plotted for samples TD024 (A), TD031 (B), and TD062 (C) for each aligner. Mean error rate per cycle was plotted against
the probability density for all 100 cycles. Generally, error rates were consistent over cycles, and there was no evidence of
a drop in accuracy over the length of the read. Estimations of mean error rates were a little on the high side (TD024, 1.3%;
TD031, 1.7%; TD062, 2.1%), likely caused by the underlying variability of HIV-2. GATK was not able to distinguish between
low-frequency variants in the viral population and sequencing errors. However, predicted mean error rates are in line with
what would be expected and are informative when choosing a cutoff frequency for reliable SNP calling.
TABLE 4 Summary statistics for the GC bias present in assembled readsa
Sample ID
Bowtie2 BWA-SW GSNAP NovoAlign
Slope Intercept Slope Intercept Slope Intercept Slope Intercept
TD024 1.80 0.17 1.95 0.10 1.74 0.19 1.79 0.15
TD031 1.04 0.54 1.17 0.47 0.97 0.56 1.02 0.54
TD062 0.66 0.70 0.88 0.57 0.35 0.81 0.56 0.71
aEstimated by ﬁtting a linear regression to the mean values in each sliding window.
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FIG 5 Scatter plots showing the GC bias in assembled reads. GC proportion and normalized depth of
coverage in each window were plotted for each aligner individually and then grouped by patient sample.
Plots are shown for patients TD024 (A), TD031 (B), and TD062 (C). A linear regression was ﬁtted to assess
the magnitude and direction of the bias. Regression lines are colored by aligner. The dashed line indicates
the expected regression in the absence of any positive or negative GC bias.
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coverage was visualized by plotting mean depth of coverage as a function of GC
content for each gene (Fig. 6). All aligners showed a similar pattern of coverage and no
consistent loss of coverage in any genomic region.
No general trends in molecular properties between the analyzed HIV-2 strains
or correlations with clinical stage. To characterize the molecular properties of the
newly generated sequences and to put them in a broader perspective, we performed
an in-depth analysis of these and the 20 selected and publicly available HIV-2 group A
sequences. Associations between molecular and biological properties were assessed by
available clinical and epidemiological data (Table S1; Fig. S2). All analyses were per-
formed per HIV-2 gene. In the data set there were two occasions of duplicate origin, i.e.,
two sequences that had been generated from the same original patient sample (Table
S1; Fig. S2, RODR and A.SN.ROD plus A.JP.NMC786_41 and A.JP.NMC786_41). These
were counted only once when assessing associations between molecular and biological
properties between sequences collected during the asymptomatic versus AIDS stage of
disease. No signiﬁcant differences in sequence length, net charge, total charge, or
number of potential N-linked glycosylation sites (PNGS), in any of the nine HIV-2 genes,
were found between sequences from asymptomatic patients (n  6) and AIDS stage
patients (n  12) (Table S1; Fig. S2). Prediction of coreceptor tropism based on the env
gp120 V3 region indicated that 50% (3 of 6) and 58% (7 of 12) of the participants had
CXCR4-using viruses in the asymptomatic and AIDS stages, respectively (P  1.00,
two-tailed Fisher’s exact test) (Table 5). Furthermore, we found no diagnostic motifs or
amino acids between asymptomatic and AIDS stage patients in any of the nine HIV-2
genes (Table S1; Fig. S2).
Genome-wide estimation of genetic diversity in HIV-2 in the context of low-
bias sequencing. To determine how the diversity varies over the HIV-2 genome, we
estimated nucleotide pairwise diversity from assembled reads (Bowtie2 assembly) using
a custom script. Raw estimates of diversity of the whole genome were 0.0010 substi-
tution/site for TD024, 0.0007 substitution/site for TD031, and 0.0014 substitution/site
for TD062. In comparison, the raw estimates for the env gene were 0.0013 substitution/
site for TD024, 0.0008 substitution/site for TD031, and 0.0020 substitution/site for
TD062. To compare the relative genetic diversity between the patients, we normalized
the raw estimates using the genome average (Fig. 7). Overall, our analysis showed
similar results between patients, with the highest level of within-host diversity seen in
env for all three patients, whereas the lowest diversity was seen in the vpx and rev
genes. Interestingly, the diversity in pol seemed to be higher than for the genes gag,
vpx, tat, rev, and vif for all three patients.
To compare the above-described results of intrahost viral diversity in different HIV-2
genes with viral diversity in different HIV-2 genes between hosts, we performed a
phylogenetic bootstrap analysis of our newly generated whole-genome sequences and
the reference sequences. This analysis showed that, similar to the intrahost viral
diversity above, the env gene was the most diverse gene, followed by the nef gene.
However, in contrast to the intrahost analysis, this analysis indicated that pol was the
second least diverse gene between hosts (only vif was less diverse [Fig. 8]).
DISCUSSION
Deep sequencing of HIV offers unparalleled opportunities to gain a high-resolution
picture of the nature and diversity of the viral quasispecies in a single patient. Our study
presents a novel pan-HIV-2 whole-genome ampliﬁcation strategy using RNA-Seq, al-
lowing the entire protein-coding region of HIV-2 to be sequenced without the need for
detailed a priori sequence knowledge. We show a broad applicability of this method,
presenting data from both lab-adapted isolates and patient plasma samples. To our
knowledge, only one previous study has used a next-generation sequencing approach
to determine the full genome of HIV-2 (35). However, we used HIV-2 isolates propa-
gated in cell culture prior to library preparation and aligned the generated sequence
reads to a common reference strain (HIV-2 BEN). We analyzed patient samples and were
able to successfully sequence samples of viral loads down to 5,280 copies/ml and an
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FIG 6 Depth of coverage as a function of genomic context. The depth of coverage was calculated
individually for each gene of the HIV-2 genome for TD024 (A), TD031 (B), and TD062 (C). Depth of coverage
was colored by aligner and plotted against the mean GC content of the gene. The predicted GC bias is
represented by the dashed line.
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expectation of at least 0.001% HIV-2 RNA in the sample. When these conditions were
fulﬁlled, the success rate was 75%, which is lower than previously reported by Batty et
al. when applying RNA-Seq to norovirus. However, the lower HIV-2 plasma viral loads
of the patient samples used in the present study readily explain this reduced success
rate. A putative cutoff of approximately 5,000 copies/ml restricts this method to viremic
HIV-2 patients, and it is possible that an alternative approach would be needed for
TABLE 5 V3 characteristics and coreceptor tropisma
Sequence name Length (aa)
Net
chargeb
Total
chargec PNGSd L18Ze V19K/Re Net>6e Ins24e
Predicted
tropismf
TD024 34 5 5 1 N N N N R5
TD031 34 5 5 1 N N N N R5
TD062 34 5 5 1 N N N N R5
CBL20 34 6 6 1 N N N N R5
RODR 36 7 7 1 N N Y N R5X4
A.CI.UC2 35 7 7 1 N N Y Y R5X4
A.DE.BEN 34 5 5 1 N N N N R5
A.DE.PEI2 35 7 9 1 N Y Y Y R5X4
A.GH.GH1 34 5 5 1 N N N N R5
A.GM.D194 35 8 8 1 N N Y Y R5X4
A.GM.ISY_SBL 35 8 10 1 N N Y Y R5X4
A.GM.MCN13 35 7 7 1 N N Y Y R5X4
A.GM.MCR35 35 7 7 1 N N Y Y R5X4
A.GW.CAM2CG 34 6 6 1 N N N N R5
A.GW.MDS 34 6 6 1 N N N N R5
A.GW.NIHZ 35 7 7 1 N N Y Y R5X4
A.IN.CRIK_147 35 7 7 1 N N Y Y R5X4
A.IN.NNVA 34 5 5 1 Y N N N R5X4
A.JP.NMC786_41 35 6 6 1 N N N Y R5X4
A.JP.NMC786_43 35 6 6 1 N N N Y R5X4
A.PT.ALI 34 6 6 1 N N N N R5
A.SN.ROD 36 7 7 1 N N Y N R5X4
A.SN.ST_JSP4_27 34 6 6 1 N N N N R5
aCoreceptor tropism was assessed as described in reference 59.
bNet charge of sequences was determined based on each lysine and arginine contributing 1 and each aspartic acid and glutamic acid contributing 1.
cTotal counts of amino acids were also assessed as described previously (58).
dNumber of potential N-linked glycosylation sites (PNGS) as deﬁned in N-GLYCOSITE (37).
eN, no; Y, yes.
fR5, CCR5-using virus; R5X4, CCR5- and CXCR4-using virus.
FIG 7 Nucleotide diversity plot. Nucleotide site diversity estimates per gene, normalized to the whole-
genome estimate. Diversity was estimated for samples TD024, TD031, and TD062. Calculation of the
diversity relative to the whole-genome estimate was performed to allow a comparison between patients.
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samples with lower viral loads. However, we anticipate that RNA-Seq could also be
successfully applied to samples taken from untreated HIV-1 patients, where the typical
viral load is 10 to 1,000 times higher than for HIV-2.
While RNA-Seq allows whole-genome sequencing of HIV-2 without the need for
detailed prior sequence knowledge, the lack of sequence-speciﬁc target ampliﬁcation
also leads to a reduction in the use of PCR ampliﬁcation and its resulting biases, thereby
generating sequence data that are more representative of the true population frequen-
cies. In this study, we aimed to quantify the other biases known to be associated with
RNA-Seq. We found evidence of a moderate positive GC bias which varied between
samples but was consistent when different aligners were used. We also found evidence
of a biased nucleotide composition in the ﬁrst 13 bases of the reads, suggesting the
presence of non-random random hexamer priming. Although these biases could be
responsible for the ﬂuctuations in coverage over the genome, we observed no corre-
lation between genomic location and depth of coverage. This suggests that these
ﬂuctuations were randomly distributed and not due to the various diversities seen in
different functional genomic sites.
While patient consensus sequences contained all nine genes of HIV-2 in intact
reading frames, there was some variability in the assembly of the 3= and 5= LTR and the
gag leader sequence. In patient sample TD031, the loss of the ﬁrst 177 bases of the gag
leader sequence could be attributed to the failure of the RNA-Seq library preparation
method to capture this region. The initial fragmentation step in library preparation can
lead to the loss of distal regions of the RNA molecule, and this is the most probable
cause of the lack of coverage in this genomic region. For patient samples TD024 and
TD062 and the reference strain CBL20, the lack of coverage was probably due to the
nature of the LTRs in HIV-2. The 5= and 3= LTR regions only exist as true 990-base
FIG 8 Median diversity between the analyzed HIV-2 strains. The median diversity was determined
phylogenetically by analysis of 200 gene-speciﬁc maximum likelihood bootstrap replicates. The error bars
show the interquartile ranges of the diversity estimates. (A) Diversity estimates in substitutions per site.
(B) Diversity estimates relative to the average median estimate of all analyzed genes (i.e., genome).
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repeats in the proviral form of the virus, whereas in the RNA genome, the 5= LTR
comprises the R and U5 regions and the 3= LTR is composed of the R and U3 regions
(36). The sequence alignment used during assembly contained HIV-2 sequences from
both cDNA and RNA HIV-2 genomes, so assembly was conducted using “complete”
LTRs, both containing U5, R, and U3 (37). Ambiguous read mapping is normally resolved
by using the location of the read mate to provide information on the most likely
coordinates. In the present study, the insert size (250 to 350 bases) and the nature of
the LTRs made mapping reads for the R region problematic, as the read mate will also
fall in the LTR. Therefore, it was not possible to resolve the correct orientation of the
reads, resulting in the loss of coverage of one LTR.
The ability to sequence the whole HIV-2 genome in a single experiment allowed us
to compare pairwise nucleotide diversities between the different HIV-2 genes. A study
comparing outcomes between HIV-1- and HIV-2-coinfected and HIV-1-monoinfected
subjects followed from early infection showed that the extent of HIV-1 genetic diversity
strongly correlated with time to AIDS (38). Much less is known about genetic diversity
in HIV-2 infection. In our small study of three subjects, all of whom presented with
raised viral load, the patterns of within-host diversity were similar in all three. The
highest diversity was seen in env, which is in keeping with previous observations in
HIV-1 infection. Diversity in partial fragments of HIV-2 env has previously been esti-
mated through different approaches, and although on the lower side, our estimated
intrahost env diversities were in the same range as those from previous studies, which
used molecular cloning for sequence generation (15, 39, 40). Similarly, a high level of
nef diversity was seen in all three patients. In HIV-1 infection, pol is thought to be highly
conserved for functional reasons and therefore typically shows a relatively lower
diversity than, for example, the env gene (41). In contrast, we observed a high level of
within-host HIV-2 pol diversity in all three subjects studied in this investigation.
Interestingly, a recent study has shown a high level of within-host diversity in pol
following vertical HIV-1 transmission (42), although vertical transmission of HIV-2 is
uncommon and is unlikely to be implicated in our study subjects. There are some
potential caveats of our intrahost diversity analysis. (i) HIV-2 diversity has been reported
to increase over the course of infection (15, 39). It is possible that parameters such as
the duration of infection or the mode of transmission inﬂuenced the diversity levels in
our study, but these parameters are not known for the three study subjects. (ii) For
some single nucleotides over the genome, the coverage was less than 20 sequence
reads, and from a sample perspective, the depth of coverage was positively correlated
with the viral copy number. On the one hand, low coverage may underestimate the
true genetic diversity. On the other hand, some regions of the genome are evolution-
arily conserved, and only a limited number of virus variants can theoretically coexist in
a sample taken from a subject with a low viral load.
vpx is an HIV-2/SIVmm speciﬁc accessory gene that is entirely absent from the
HIV-1/SIVcpz lineage. The main role of vpx is antagonism of the host restriction factor
SAMHD1, which blocks reverse transcription of viral RNA in slowly dividing cells, such
as macrophages and resting CD4 T cells (43). Our observation of a consistently low
level of vpx diversity may indicate a high level of conservation in vpx, suggesting that
vpx has a critical role in HIV-2 pathogenesis. The implications of vpx diversity in HIV-2
infection are not yet clearly deﬁned, but a recent study by Yu et al. identiﬁed an SNP
in a vpx allele derived from a viremic patient that totally abrogated the ability of vpx to
promote SAMHD1 degradation in vitro (44).
In conclusion, we show that RNA-Seq library preparation methods can be applied to
HIV-2 blood plasma samples. Resulting de novo genome assemblies captured the entire
coding region of HIV-2 in intact open reading frames and read remapping allowed us
to demonstrate the importance of a two-step analysis pipeline. In the context of a
highly diverse retrovirus, such as HIV-2, the selection or generation of an appropriate
reference sequence is a critical ﬁrst step, allowing robust and repeatable downstream
read mapping. We also demonstrated a low level of GC and random-hexamer bias and,
in the absence of sequence-speciﬁc target ampliﬁcation, showed that RNA-Seq offers a
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method of whole-genome HIV-2 sequencing in a low bias context. However, some
challenges in RNA-Seq remain. For example, although the sequencing costs have fallen
dramatically in recent years, RNA-Seq is still expensive and costs continue to be a
barrier to an even more widespread adoption. In the present study, we multiplexed six
patient samples using the Illumina HiSeq in order to reach a mean depth of coverage
of up to 67. Although this coverage is more than sufﬁcient for consensus sequence
calling, it may be too low if the primary goal is to determine minority variants (at least
in samples with high viral loads). Hence, the importance of developing novel and
low-bias HIV sequencing protocols cannot be overstated, as the ability to gain a
complete and accurate picture of HIV genetic diversity is critical to the development of
globally effective and preventative HIV vaccines.
MATERIALS AND METHODS
Patient sample collection. All patient samples used in the present study were collected from
members of the Caió community cohort who had provided written and informed consent. Samples were
collected prior to the start of the present study. Plasma was separated from whole blood through
centrifugation (5,000  g, 5 min, and 4°C) and ﬁltration (0.45-m ﬁlter; Millipore, Billerica, MA). Plasma
samples were stored at 80°C before being transported to Oxford, United Kingdom, in a liquid nitrogen
dry shipper. None of the samples used had any record of previous freeze-thaw cycles.
In vitro culture of lab-adapted HIV-2 reference strains. The lab-adapted HIV-2 strains HIV-2 ROD
and HIV-2 CBL20 were propagated in vitro in the lymphocyte cell line H9, a single cell clone derived from
a HUT 78 cell line. Infection of 5  106 cells was carried out with 200 l of 9  103 50% tissue culture
infective doses (TCID50)/ml of viral stock. Cells were removed through centrifugation at 250  g for 10
min, and supernatant was collected on days 3, 5, 7, 9, 11, 13, and 15. HIV-2 concentrations were assayed
using a colorimetric reverse transcriptase assay (Roche). For each isolate, the supernatant sample with
the highest reverse transcriptase concentration was selected for RNA-Seq.
RNA extraction, RNA quantification, and DNase treatment. Total nucleic acid was extracted
directly from 500 l of patient plasma or puriﬁed supernatant using the QIAamp UltraSens viral kit
(Qiagen). Extraction was performed according to the manufacturer’s protocol, with the substitution of
carrier RNA with linear acrylamide (Ambion) as the nucleic acid coprecipitant. Final elution was per-
formed in 12 l of H2O. DNA was removed from the samples through treatment with DNase I (Turbo
DNase; Ambion) according to the manufacturer’s protocol. RNA concentration was estimated using the
QuBit RNA assay (Invitrogen).
Library preparation and sequencing. Sequencing libraries were prepared from 5 l of the eluted
RNA using the NEBNext Ultra RNA library prep kit for Illumina (New England BioLabs) according to the
manufacturer’s protocol. Sequencing libraries were multiplexed and sequenced using the Illumina HiSeq
or MiSeq platform (Illumina). Patient samples were multiplexed at 6/lane (HiSeq), generating 2  100
nucleotide paired-end reads, and lab-adapted strains were multiplexed at 2/lane (MiSeq), generating
2  150 nucleotide paired-end reads.
De novo genome assembly and read remapping. Sequence data were analyzed using a custom
pipeline. Reads were trimmed using Sickle, stipulating a median Q-score of 30 and a read length of 40
bp (45). De novo genome assembly was performed using VICUNA (46), with the addition of the optional
contamination removal step. During contamination removal, HIV-2-derived reads were identiﬁed
through similarity to a multiple-sequence alignment containing a set of 18 publicly available HIV-2 group
A sequence data (Table S1). Overlapping contiguous sequences generated by VICUNA were assembled
into whole-genome sequences using the map-to-reference feature in Geneious v6.1.6 (47) and manually
inspected to derive a whole-genome consensus sequence. Consensus genome sequences were manually
inspected to ensure that they contained intact open reading frames. Reads were remapped to the
consensus genome sequence using Bowtie2 (48), BWA-SW (49), GSNAP (50), and NovoAlign (51) for each
sample. Files containing assembled reads were manipulated using the SAMtools package (52), and
downstream statistical analyses and data visualizations were performed using R (53) and the Interactive
Genome Viewer (54). Error rates were estimated using the ErrorRatePerCycle feature of GATK (55).
Quantification of biases. Random-hexamer bias was assessed through visualization of the base
composition of reads using FASTQC (56). GC bias was quantiﬁed using a custom Python script that
scanned the genome using a 50-bp sliding window with a step size of 20 bp. Mean GC content and mean
depth of coverage were computed for each window, and GC bias was assessed by ﬁtting a linear
regression in R (57).
Analysis of molecular properties. Analyses of molecular properties were performed using an
in-house Perl script with potential N-linked glycosylation sites (PNGS) as deﬁned in N-GLYCOSITE (37). Net
charge of sequences was determined based on each lysine and arginine contributing 1 and each
aspartic acid and glutamic acid contributing 1. Total counts of amino acids were assessed as described
previously (58). Coreceptor tropism was predicted using four major determinants of dual/CXCR4 core-
ceptor use (L18Z, V19K/R, V3 net charge of 6, and insertions at position 24) (59). CXCR4 use was
considered when at least one of the criteria was fulﬁlled. Sample donors were classiﬁed as having been
sampled during either the asymptomatic or AIDS stage (as deﬁned by clinical assessment at the sample
time point).
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Phylogenetic analysis. A reference set of 20 HIV-2 group A whole-genome sequences were
obtained from the Los Alamos HIV database (Table S1) (37). Reference sequences were aligned with
consensus whole-genome sequences using Muscle (60), and the alignment was manually inspected
using Geneious v6.1.6. A Bayesian phylogeny was inferred using BEAST v1.8.0 (61), under the general
time-reversible model of nucleotide substitution with a proportion of invariant sites and gamma-
distributed rate heterogeneity, as determined by jModelTest2 (57). The Markov Chain Monte Carlo
algorithm was run using 100,000,000 iterations with samples taken from the posterior distribution every
10,000 generations. Following a burn-in corresponding to 10% of the samples, the resulting maximum
clade credibility (MCC) tree was visualized using FigTree v1.4.1 (62).
Estimation of genetic diversity. Mpileup ﬁles were generated from assembled reads using the
SAMtools package, and variants were called using VarScan (63) with a cutoff frequency of 0.05.
Nucleotide pairwise diversity () was estimated using the Nei and Li method (64) through a custom
Python script, taking depth at each position as a proxy for population size and the product of frequency
of alternative variants and depth as the number of pairwise differences between sequences. Estimates of
diversity were generated for each individual gene and over the whole genome, and estimates were
normalized using the whole-genome average to allow comparison between patients. For comparison, we
also calculated diversity at the population level by averaging pairwise phylogenetic tree distances in Garli
v2.0 (65). This was done for each gene separately based on 200 maximum likelihood bootstrap replicates
as described previously (58).
Statistics. Two-tailed Fisher’s exact test was used to assess data (IBM SPSS Statistics for Windows,
v23.0; IBM Corp., Armonk, NY).
Ethics. Ethical approval was granted by the Gambian government/MRC joint ethics committee
(SCC1204) and the Oxford tropical research ethics committee (170-12).
Accession number(s). Nucleotide sequences were deposited in GenBank under the following
accession numbers: MH681607 to MH681611.
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